AU2021324538A1 - Method for the treatment of wwox associated diseases - Google Patents

Method for the treatment of wwox associated diseases Download PDF

Info

Publication number
AU2021324538A1
AU2021324538A1 AU2021324538A AU2021324538A AU2021324538A1 AU 2021324538 A1 AU2021324538 A1 AU 2021324538A1 AU 2021324538 A AU2021324538 A AU 2021324538A AU 2021324538 A AU2021324538 A AU 2021324538A AU 2021324538 A1 AU2021324538 A1 AU 2021324538A1
Authority
AU
Australia
Prior art keywords
wwox
promoter
gene
brain
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021324538A
Other languages
English (en)
Inventor
Rami Aqeilan
Srinivas REPUDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU2021324538A1 publication Critical patent/AU2021324538A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021324538A 2020-08-11 2021-08-11 Method for the treatment of wwox associated diseases Pending AU2021324538A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063064181P 2020-08-11 2020-08-11
US63/064,181 2020-08-11
US202163167277P 2021-03-29 2021-03-29
US63/167,277 2021-03-29
PCT/IL2021/050982 WO2022034591A1 (en) 2020-08-11 2021-08-11 Method for the treatment of wwox associated diseases

Publications (1)

Publication Number Publication Date
AU2021324538A1 true AU2021324538A1 (en) 2023-03-09

Family

ID=77910831

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021324538A Pending AU2021324538A1 (en) 2020-08-11 2021-08-11 Method for the treatment of wwox associated diseases

Country Status (9)

Country Link
US (1) US20230293726A1 (enExample)
EP (2) EP4582143A3 (enExample)
JP (1) JP7850136B2 (enExample)
KR (1) KR20230051223A (enExample)
AU (1) AU2021324538A1 (enExample)
CA (1) CA3188895A1 (enExample)
ES (1) ES3032462T3 (enExample)
IL (1) IL300374A (enExample)
WO (1) WO2022034591A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116463413A (zh) * 2023-06-12 2023-07-21 佛山科学技术学院 猪间性病相关的wwox基因分子标记及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025264815A1 (en) * 2024-06-18 2025-12-26 Synaptec Network, Inc. Systems and methods of exosome mediated delivery of antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060811B2 (en) * 2000-10-13 2006-06-13 Board Of Regents, The University Of Texas System WWOX: a tumor suppressor gene mutated in multiple cancers
US20090270484A1 (en) * 2005-10-05 2009-10-29 The Ohio State University Research Foundation WWOX Vectors and Uses in Treatment of Cancer
DK2282779T3 (da) * 2008-04-29 2013-05-27 Pharnext Nye terapeutiske fremgangsmåder til behandling af alzheimer sygdom og beslægtede lidelser gennem en modulation af cellestress-respons
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
CN112301024A (zh) 2013-03-15 2021-02-02 通用医疗公司 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
WO2017147720A1 (en) * 2016-03-04 2017-09-08 Exerkine Corporation Method for treating a central nervous system disorder
KR20210053877A (ko) * 2018-06-26 2021-05-12 리보노바 인크. 미토콘드리아 기능장애를 치료하는 방법
KR20220094216A (ko) * 2019-11-08 2022-07-05 코브 테라퓨틱스 변형된 아데노-관련 바이러스 벡터 및 이의 중추신경계로의 전달

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116463413A (zh) * 2023-06-12 2023-07-21 佛山科学技术学院 猪间性病相关的wwox基因分子标记及其应用
CN116463413B (zh) * 2023-06-12 2023-10-03 佛山科学技术学院 猪间性病相关的wwox基因分子标记及其应用

Also Published As

Publication number Publication date
ES3032462T3 (en) 2025-07-18
EP4582143A2 (en) 2025-07-09
KR20230051223A (ko) 2023-04-17
CA3188895A1 (en) 2022-02-17
EP4196595B1 (en) 2025-03-12
WO2022034591A1 (en) 2022-02-17
JP2023537093A (ja) 2023-08-30
EP4196595A1 (en) 2023-06-21
US20230293726A1 (en) 2023-09-21
JP7850136B2 (ja) 2026-04-22
IL300374A (en) 2023-04-01
EP4582143A3 (en) 2025-10-22

Similar Documents

Publication Publication Date Title
Steinberg et al. Modeling genetic epileptic encephalopathies using brain organoids
Liu et al. Ascl1 converts dorsal midbrain astrocytes into functional neurons in vivo
Repudi et al. Neuronal deletion of Wwox, associated with WOREE syndrome, causes epilepsy and myelin defects
Mei et al. Stage-specific deletion of Olig2 conveys opposing functions on differentiation and maturation of oligodendrocytes
Tung et al. Mir-17∼ 92 confers motor neuron subtype differential resistance to ALS-associated degeneration
Nishino et al. A network of heterochronic genes including Imp1 regulates temporal changes in stem cell properties
US20190099452A1 (en) Methods for promoting oligodendrocyte regeneration and remyelination
US20180051259A1 (en) Cell fate conversion of differentiated somatic cells into glial cells
EP4196595B1 (en) Method for the treatment of wwox associated diseases
US20190322981A1 (en) Means and methods for the generation of oligodendrocytes
US20240108758A1 (en) Compounds, compositions, and methods for using hla-f
US20210228741A1 (en) Methods and compositions to stimulate retinal regeneration
Deng et al. Let-7f promotes the differentiation of neural stem cells in rats
CN111686124B (zh) miR-486-3p在制备治疗SAH导致的神经炎症产品中的应用
CA3194085A1 (en) Compositions and methods for modulating tcf4 gene expression and treating pitt hopkins syndrome
Zhou et al. MiR-138 reprograms dental pulp stem cells into GABAergic neurons via the GATAD2B/MTA3/WNTs axis for stroke treatment
Liu et al. Single‐Cell RNA Sequencing Uncovers Molecular Features Underlying the Disrupted Neurogenesis Following Traumatic Brain Injury
CN116457025A (zh) 用于治疗wwox相关疾病的方法
Fu et al. Comparative transcriptomic profiling reveals a role for Olig1 in promoting axon regeneration
Obeid et al. Neuron-Specific WWOX Gene Therapy Produces Dose-Dependent, Durable Rescue in a Model of WWOX-Related Epileptic Encephalopathy
Africano Transcriptomic analysis of the effects of PHOX2B polyAla expansions in cellular models of Congenital Central Hypoventilation Syndrome
Baughn Therapeutic Restoration of Stathmin-2 RNA Processing in TDP-43 Proteinopathies
Abati In vivo and in vitro evaluation of the combination of RNA interfering and gene therapy for treating Mitofusin2-related diseases
Alarcon-Martineza et al. Characterization of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina
Rizzo et al. Combined RNA interference and gene replacement therapy targeting MFN2 for the treatment of Charcot-Marie-Tooth type 2A